Newsroom

Vaccination on the upper arm.
News
Researchers at the Helmholtz Centre for Infection Research (HZI) have developed a promising new vaccine technology. Their studies to date show that just one dose of vaccine leads to effective and long-lasting immune protection. The basis of this so-called MCMV vaccine vector technology is the mouse cytomegalovirus (MCMV). It acts as a carrier virus that introduces selected antigens of a pathogen to be vaccinated against into the body. In the follow-up project VIVA-VEK-2, which was launched at the HZI at the beginning of January, a proof-of-concept vaccine candidate against respiratory syncytial virus (RSV) is now to be produced and tested for efficacy and tolerability. The researchers believe that with the new vaccine technology, one vaccine dose could possibly even provide lifelong protection. The project is funded by the GO-Bio initial program of the Federal Ministry of Education and Research (BMBF) over two years with a funding volume of one million euros.
07.01.2025
The Horizon Europe project DEFENDER is exploring new targets for antiviral therapies
News
The interdisciplinary project DEFENDER is developing innovative approaches to combat (re-)emerging viruses. The project, coordinated by the Leibniz Institute of Virology (LIV), is being funded with around eight 9.6 million euros as part of Horizon Europe. Almost 700,000 euros of these will go to Prof. Mark Brönstrup, a researcher at the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection Research (DZIF).
06.01.2025
Isolated bacteria
News
A research team from the Helmholtz Institute for One Health (HIOH) has investigated the distribution and characteristics of multidrug-resistant bacteria in the Baltic Sea. The findings prove that resistant pathogens occur not only in samples taken from clinical settings but also from the environment. The BMBF-funded study also underlines the importance of an integrated strategy for combatting multidrug resistance that takes equal account of environmental and health protection. The results were published recently in the scientific journal npj Clean Water.
23.12.2024
 Scanning electron micrograph of Mycobacterium tuberculosis
News
Global migration has increased in recent decades due to war, conflict, persecutions, and natural disasters, but also secondary to increased opportunities related to work or study. A group of international experts that collaborate in the Tuberculosis Network European Trialsgroup (TBnet), led by Heinke Kunst from Queen Mary College of London, Berit Lange from the Epidemiology Department at the Helmholtz Centre for Infection Research (HZI), Christoph Lange from the Research Center Borstel and Anca Vasiliu from Baylor College of Medicine, has now identified the risk for tuberculosis and comorbidities in migrants to the European Union/European Economic Area and the United Kingdom (EU/EEA/&UK).
19.12.2024
Cultures of different Streptomyces strains
News
Microorganisms produce a wide variety of natural products that can be used as active ingredients to treat diseases such as infections or cancer. The blueprints for these molecules can be found in the microbes' genes, but often remain inactive under laboratory conditions. A team of researchers at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now developed a groundbreaking genetic method that leverages a natural bacterial mechanism for the transfer of genetic material and uses it for the production of new active ingredients. The team published its results in the journal Science.
13.12.2024
HZI website on various end devices and Typo3 award
News
In April 2024, the Helmholtz Centre for Infection Research (HZI) completely revamped its website together with the digital agency +Pluswerk. The aim of this relaunch was to present the HZI and its scientific work to the public in an appealing, contemporary design. The new HZI website has now won the TYPO3 Award in the “Health” category. The award was presented at the TYPO3 Conference 2024 in Düsseldorf.
09.12.2024

HZI in the media

... Dr. rer. nat. Jakob Wirbel vom Helmholtz-Zentrum für Infektionsforschung (Braunschweig). Das Experiment aus Stanford sei ...

20.02.2026
|
Deutsches Ärzteblatt

... unseres Immunsystems zu entziehen. Strukturbiologen des Helmholtz-Zentrums für Infektionsforschung (HZI) konnten nun mittels ...

18.02.2026
|
Bionity.COM

of our immune system. Structural biologists at the Helmholtz Center for Infection Research (HZI) have now used cryo-electron microscopy to

16.02.2026
|
Phys.org

Was es mit Mpox – früher Affenpocken genannt – auf sich hat, welche Symptome erkrankte Personen haben und wie man sich anstecken kann.

13.02.2026
|
Apotheken Umschau

Julia Port, research group leader at Germany's Helmholtz Center for Infection Research.

 

"Ongoing outbreaks—particularly those driven by

12.02.2026
|
Medical Xpress

... Livia Patrono, laut einer Mitteilung des beteiligten Helmholtz-Instituts für One Health (HIOH): Denn dadurch ...

12.02.2026
|
n-tv

... für den Neubau der Klinik für Strahlentherapie Würzburg sowie für das Helmholtz-Institut für RNA-basierte ...

12.02.2026
|
mainpost.de

Project

 

Researchers at the Helmholtz Institute for One Health (HIOH), a site of the Helmholtz Centre for Infection Research (HZI), together

11.02.2026
|
NewsBreak

by Prof. Hortense Slevogt, Hannover Medical School, and Helmholtz Centre for Infection Research, shows that the treatment with PulmoPlas®

10.02.2026
|
Biotech Investments

... der Medizinischen Hochschule Hannover und des Helmholtz-Zentrums für Infektionsforschung. „Unsere Methode erfordert nur einen ...

10.02.2026
|
Health Capital

Fermentation und Aufreinigung, wurde ebenfalls am HZI in der Arbeitsgruppe von Prof. Marc Stadler, stellvertretender ...

06.02.2026
|
juraforum.de

... gehört habt: Phagen. Spoiler: Was am Helmholtz-Zentrum für Infektionsforschung (HZI) passiert, rettet im Zweifel Leben – ...

05.02.2026
|
Redaktionsnetzwerk Deutschland

Register now for the HZI-Newsletter